

Supplementary material- Figure S1

Supplementary Figure S1. In vitro antimicrobial spectrum for newer antibiotics used for nosocomial pneumonia. Each colour is based on current reported in vitro antibiotic susceptibility rates; these rates are indicative and may differ in different reports depending on cohorts and cut-offs used (EUCAST versus CLSI), and as new real-world in vitro sensitivity data arise constantly.

Antibiotic-susceptibility rate			
81-	61-	41-	≤ 40%

Antibiotic	Enterobacterales					<i>Pseudomonas aeruginosa</i>				<i>Acinetobacter baumannii</i>
	Ambler Class A ESBLs	Ambler Class A KPC	Ambler Class B MBLs [^]	Ambler Class C	Ambler Class D OXA-48 like	AmpC de-repression	Efflux Pump Over-expression	Deficient OprD expression	MBLs [^]	CRAB
Ceftolozane-tazobactam				~						
Ceftazidime-avibactam										
Meropenem-vaborbactam										
Imipenem-cilastatin-relebactam ^{&}										
Cefiderocol [*]			V I M	N D M [#]					^*	*

- Duda-Madej A, Viscardi S, Topola E. Meropenem/Vaborbactam: β -Lactam/ β -Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance. *Antibiotics (Basel)*. 2023 Nov 10;12(11):1612. doi: 10.3390/antibiotics12111612. PMID: 37998814; PMCID: PMC10668789.
- Dequin PF, Aubron C, Faure H, Garot D, Guillot M, Hamzaoui O, Lemiale V, Maizel J, Mootien JY, Osman D, Simon M, Thille AW, Vinsonneau C, Kuteifan K. The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference. *Ann Intensive Care*. 2023 Jul 4;13(1):59. doi: 10.1186/s13613-023-01155-4. PMID: 37400647; PMCID: PMC10317910.
- Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI Pseudomonas Study Group. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β -Lactam-Resistant Mutants. *Antimicrob Agents Chemother*. 2020 Jan 27;64(2):e02165-19. doi: 10.1128/AAC.02165-19. PMID: 31740559; PMCID: PMC6985745.
- Granata G, Taglietti F, Schiavone F, Petrosillo N. Durlobactam in the Treatment of Multidrug-Resistant *Acinetobacter baumannii* Infections: A Systematic Review. *J Clin Med*. 2022 Jun 7;11(12):3258. doi: 10.3390/jcm11123258. PMID: 35743328; PMCID: PMC9225462.
- Iregui A, Khan Z, Landman D, Quale J. Activity of Cefiderocol Against *Enterobacteriales*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* Endemic to Medical Centres in New York City. *Microb Drug Resist*. 2020 Jul;26(7):722-726. doi: 10.1089/mdr.2019.0298. Epub 2020 Feb 7. PMID: 32031915; PMCID: PMC7368386.
- Kanj S, Bassetti M, Kiratisin P, Rodrigues R, Villegas MR, Yunsong Yu Y, van Duin D. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. *International Journal of Antimicrobial Agents*. 2022; 60(3):106633. doi: 10.1016/j.ijantimicag.2022.106633. Epub 2022 Jul 1. PMID: 35787918.
- Karakonstantis S, Rousaki M, Kritsotakis EI. Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. *Antibiotics (Basel)*. 2022 May 27;11(6):723. doi: 10.3390/antibiotics11060723. PMID: 35740130; PMCID: PMC9220290.
- Karakonstantis S, Rousaki M, Vassilopoulou L, Kritsotakis EI. Global prevalence of cefiderocol non-susceptibility in Enterobacteriales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2024 Feb;30(2):178-188. doi: 10.1016/j.cmi.2023.08.029. Epub 2023 Sep 4. PMID: 37666449.
- Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. *J Antimicrob Chemother*. 2013 Oct;68(10):2286-90. doi: 10.1093/jac/dkt178. Epub 2013 May 21. PMID: 23696619.
- Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, de Waele J, Daikos GL, Akova M, Harbarth S, Pulcini C, Garnacho-Montero J, Seme K, Tumbarello M, Lindemann PC, Gandra S, Yu Y, Bassetti M, Mouton JW, Tacconelli E, Rodríguez-Baño J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). *Clin Microbiol Infect*. 2022 Apr;28(4):521-547. doi: 10.1016/j.cmi.2021.11.025. Epub 2021 Dec 16. PMID: 34923128.
- Robin F, Auzou M, Bonnet R, et al. In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different β -lactam resistance phenotypes. *Antimicrob Agents Chemother* 2018; 62:e00675-18.
- Shortridge D, Kantro V, Castanheira M. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant *Enterobacteriales* Strains, Including Carbapenem-Resistant Isolates. *Microbiol Spectr*. 2023 Feb 14;11(1):e0450722. doi: 10.1128/spectrum.04507-22. Epub 2023 Jan 9. PMID: 36622238; PMCID: PMC9927278.
- Viale P, Sandrock CE, Ramirez P, Rossolini GM, Lodise TP. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence. *Ann Intensive Care*. 2023 Jun 15;13(1):52. doi: 10.1186/s13613-023-01146-5. PMID: 37322293; PMCID: PMC10272070.
- Wi YM, Greenwood-Quaintance KE, Schuetz AN, Ko KS, Peck KR, Song JH, Patel R. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms. *Antimicrob Agents Chemother*. 2017 Dec 21;62(1):e01970-17. doi: 10.1128/AAC.01970-17. PMID: 29133568; PMCID: PMC5740377.